CorriXR Therapeutics Announces Publication of Additional Preclinical Data Corroborating Ability of NRF2 Knockout to Restore Chemosensitivity in Solid Tumors

CorriXR Therapeutics Announces Publication of Additional Preclinical Data Corroborating Ability of NRF2 Knockout to Restore Chemosensitivity in Solid Tumors

Peer-reviewed results in Molecular Therapy Oncology show that targeted, mutation-agnostic CRISPR gene editing of NRF2 in head and neck cancer models resensitizes treatment resistant tumors to chemotherapies.NEWARK, Del.--(BUSINESS WIRE)--#CRISPR--A new publication from CorriXR Therapeutics, an oncology focused biotherapeutics company developing genetic medicines to overcome drug resistance in solid tumors, shows that its novel CRISPR-directed di…